• Explore /
  • Poster
  • / Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

Abstract Poster

Authors

Michael Morris

Michael J. Morris

Memorial Sloan Kettering Cancer Center, New York, NY

Michael J. Morris , Yohann Loriot , Christopher Sweeney , Karim Fizazi , Charles J. Ryan , Daniel H. Shevrin , Emmanuel S. Antonarakis , John Reeves , Kumari Chandrawansa , Martin Kornacker , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Other Prostate, Testicular, or Penile Cancer

Clinical Trial Registration Number

NCT01106352

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5075)

DOI

10.1200/JCO.2016.34.15_suppl.5075

Abstract #

5075

Poster Bd #

332

Abstract Disclosures

Similar Posters

First Author: Michael J. Morris

First Author: Michael J. Morris

First Author: Nicholas J. Vogelzang

First Author: Nicholas D. James